10-Q · May 12, 2026
Olema Pharmaceuticals reported a significant increase in net loss, reaching $53.1 million in Q1 2026 compared to $30.4 million in Q1 2025, with cash reserves of $505.3 million. The company continues to focus on…
Earnings analysis · 10-Q
OLMA earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text provides limited current-period financial statement detail, but it reports a $63.2 million quarterly net loss versus $43.8 million a year earlier and an accumulated deficit of $713.8 million.…
Read full summary
The supplied 10-Q text provides limited current-period financial statement detail, but it reports a $63.2 million quarterly net loss versus $43.8 million a year earlier and an accumulated deficit of $713.8 million. Olema continues to invest in multiple clinical programs, but management states that existing cash, cash equivalents and marketable securities will not fund all activities required to complete palazestrant and OP-3136 development. Funding needs, clinical execution, third-party manufacturing dependence and potentially substantial pharmaceutical tariffs create a negative risk/reward profile, with no quantitative financial guidance provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Pipeline investment continues
Olema reported net losses of $63.2 million for the three months ended June 30, 2026, compared with $43.8 million in the comparable 2025 period. The company states that losses are expected to continue for the foreseeable future.
-
Clinical organization expanded
The company had 150 full-time employees as of June 30, 2026, including 39 employees with Ph.D. or M.D. degrees, supporting concurrent clinical development programs for palazestrant and OP-3136.
-
Debt maturity extended
The loan facility maturity date was extended to January 1, 2029, with potential further extension to July 1, 2029 if specified development or financing milestones occur.
-
Controls remain effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
-
No material litigation or sales
The company reported no material legal proceedings and no unregistered equity sales during the period covered by the report.
-
Multiple clinical programs advancing
Olema continued development of palazestrant across multiple indications, including OPERA-02, a Phase 3 trial combining palazestrant with ribociclib, and clinical development of OP-3136.
What to watch
-
Funding and going-concern risk
The company has accumulated a deficit of $713.8 million as of June 30, 2026 and states that existing cash, cash equivalents and marketable securities will not fund all activities necessary to complete development of palazestrant and OP-3136.
-
Debt covenant and default risk
Olema had an outstanding liability of $3.0 million under its credit facility as of December 31, 2025. The loan agreement contains covenants and customary events of default that could permit acceleration of repayment obligations.
-
Tariffs may raise trial costs
The company states that tariffs of up to 100% on certain patented pharmaceuticals and associated ingredients are scheduled to become effective September 29, 2026, unless reduced, modified or terminated. Management expects tariffs to increase R&D costs and potentially disrupt clinical-trial supply chains.
-
Clinical and regulatory execution
Olema has no products approved for commercial sale and has never completed a pivotal clinical trial or submitted an NDA. Failure of palazestrant or OP-3136 clinical development would prevent product revenue generation.
-
Third-party supply concentration
The company relies on third-party manufacturers and states that raw materials for palazestrant and OP-3136 are sourced in some cases from a single-source supplier, creating potential for clinical-trial delays or interruptions.
-
Potential reporting-cost increase
Olema expects that it will no longer qualify as a smaller reporting company based on its market value at the end of the second fiscal quarter of 2026. Losing that status could increase legal, accounting and financial compliance costs.
Management's outlook
No quantitative revenue or EPS guidance is provided in the supplied 10-Q text. The filing states that the company does not anticipate generating product-sale revenue for the next several years, if ever.
Earlier filings 4
10-K · March 16, 2026
Olema is a clinical-stage oncology company advancing its lead oral ER CERAN/SERD palazestrant through pivotal development and an early-stage KAT6 program (OP-3136). The 10-K highlights clear clinical timelines (OPERA-01…
10-K · March 18, 2025
Olema is a clinical‑stage biopharmaceutical company advancing palazestrant (OP‑1250) in a pivotal Phase 3 (OPERA‑01) with anticipated top‑line results in 2026 and preparing a Phase 3 combination trial (OPERA‑02) with…
10-Q · May 8, 2024
Olema reported no product revenue and a net loss of $30,970,000 (net loss per share $0.56) for the three months ended March 31, 2024, driven by higher R&D spending. Cash, cash equivalents and marketable securities…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.